Bio-TechneTECHEarnings & Financial Report
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
TECH Q3 FY2026 Key Financial Metrics
Revenue
$311.4M
Gross Profit
$208.3M
Operating Profit
$75.5M
Net Profit
$51.0M
Gross Margin
66.9%
Operating Margin
24.2%
Net Margin
16.4%
YoY Growth
-1.5%
EPS
$0.32
Bio-Techne Q3 FY2026 Financial Summary
Bio-Techne reported revenue of $311.4M (down 1.5% YoY) for Q3 FY2026, with a net profit of $51.0M (up 126.0% YoY) (16.4% margin). Cost of goods sold was $103.1M, operating expenses totaled $132.8M.
Key Financial Metrics
| Total Revenue | $311.4M |
|---|---|
| Net Profit | $51.0M |
| Gross Margin | 66.9% |
| Operating Margin | 24.2% |
| Report Period | Q3 FY2026 |
Revenue Breakdown
Bio-Techne Q3 FY2026 revenue of $311.4M breaks down across 3 segments, led by Protein Sciences segment revenue at $226.2M (72.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Protein Sciences segment revenue | $226.2M | 72.6% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27.5% |
| Other revenue (1) | $5.4M | 1.7% |
Bio-Techne Annual Revenue by Year
Bio-Techne annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.2B).
Bio-Techne Quarterly Revenue & Net Profit History
Bio-Techne results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $311.4M | -1.5% | $51.0M | 16.4% |
| Q2 FY2026 | $295.9M | -6.4% | $38.0M | 12.8% |
| Q4 FY2025 | $317.0M | +3.5% | $-17.7M | -5.6% |
| Q3 FY2025 | $316.2M | +4.2% | $22.6M | 7.1% |
| Q2 FY2025 | $297.0M | +9.0% | $34.9M | 11.7% |
| Q1 FY2025 | $289.5M | +4.5% | $33.6M | 11.6% |
| Q4 FY2024 | $306.1M | +1.6% | $40.6M | 13.3% |
| Q3 FY2024 | $303.4M | +3.2% | $49.1M | 16.2% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $303.4M | $306.1M | $289.5M | $297.0M | $316.2M | $317.0M | $295.9M | $311.4M |
| YoY Growth | 3.2% | 1.6% | 4.5% | 9.0% | 4.2% | 3.5% | -6.4% | -1.5% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.72B | $2.70B | $2.74B | $2.67B | $2.64B | $2.56B | $2.52B | $2.55B |
| Liabilities | $706.8M | $635.0M | $597.4M | $591.9M | $626.2M | $639.1M | N/A | $465.3M |
| Equity | $2.01B | $2.07B | $2.14B | $2.08B | $2.02B | $1.92B | $2.01B | $2.09B |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $81.0M | $75.5M | $63.9M | $84.3M | $41.1M | $98.2M |